{"id":1020240,"date":"2026-11-12T08:37:28","date_gmt":"2026-11-12T13:37:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-third-quarter-2026-financial-results-and-provides-business-updates\/"},"modified":"2026-11-12T08:37:28","modified_gmt":"2026-11-12T13:37:28","slug":"parabilis-medicines-reports-third-quarter-2026-financial-results-and-provides-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/parabilis-medicines-reports-third-quarter-2026-financial-results-and-provides-business-updates\/","title":{"rendered":"Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates"},"content":{"rendered":"
\n

\n Presented updated Phase 1\/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors<\/em>\n <\/p>\n

\n Reached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL Phase 3 registrational trial in desmoid tumors<\/em>\n <\/p>\n

\n Initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis (FAP)<\/em><\/p>\n

Entered into a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination with zoldonrasib and cetuximab in patients with previously treated <\/em>
\n RAS G12D mutant<\/em>
\n microsatellite stable metastatic colorectal cancer (MSS CRC)<\/em>\n <\/p>\n

\n Ended the third quarter with $1.1 billion in cash, cash equivalents and marketable securities, expected to fund operations into 2030<\/em>\n <\/p>\n

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today reported financial results and business updates for the third quarter ended September 30, 2026.<\/p>\n

\u201cWith each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases,\u201d said Mathai Mammen, M.D., Ph.D., Chairman, Chief Executive Officer and President of Parabilis Medicines. \u201cThe updated results presented at ESMO further reinforce our confidence in the depth and consistency of desmoid tumor responses, alongside a favorable safety and tolerability profile. With our Phase 3 dosing, regimen and trial design aligned with the FDA, we are well positioned to initiate PEDESTAL in the first half of 2027, bringing us closer to delivering a potentially transformative treatment for patients with desmoid tumors.\u201d<\/p>\n

Dr. Mammen continued, \u201cWe are also continuing to deliver on zolucatetide\u2019s potential to become a pipeline in a product, advancing development in FAP, adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and other Wnt-driven diseases, while pursuing a scientifically grounded combination approach in MSS CRC through our collaboration with Revolution Medicines. In parallel, we are selectively advancing a broader pipeline of programs against other historically undruggable targets. The progress across our portfolio continues to strengthen our conviction in the ability of our HeliconTM<\/sup> platform to repeatedly translate breakthrough science into medicines that can meaningfully improve patients\u2019 lives.\u201d<\/p>\n

\n Recent Business Highlights and Anticipated Milestones<\/strong>\n <\/p>\n

\n Continued Advancement of Zolucatetide<\/strong>\n <\/p>\n

\n Desmoid tumors<\/strong>\n <\/p>\n